A phase II study presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium showed that CTX-009 combined with paclitaxel administered as second- or third-line therapy in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback